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Abstract
Background: Stroke is a common cause of cognitive impairment and dementia. However, effective strategies for
reducing the risk of post-stroke dementia remain undefined. Potential strategies include intensive lowering of blood
pressure and/or lipids.
Methods/Design: Design: multi-centre prospective randomised open-label blinded-endpoint controlled
partial-factorial phase IV trial in secondary and primary care.
Participants: 100 participants from 30 UK Stroke Research Network sites who are post- ischemic stroke or
intracerebral haemorrhage by three to seven months.
Interventions - all patients (1:1): intensive versus guideline blood pressure lowering (target systolic < 125 mmHg
versus < 140 mmHg).
Interventions - ischemic stroke (1:1): intensive versus guideline lipid lowering (target low density
lipoprotein-cholesterol (LDL-c) < 1.4 mmol/l versus < 3 mmol/l).
Hypotheses: does ‘intensive’ blood pressure lowering therapy and/or ‘intensive’ lipid control reduce cognitive
decline and dementia in people with ischemic stroke; and does ‘intensive’ blood pressure lowering therapy reduce
cognitive decline and dementia in patients with hemorrhagic stroke.
Primary outcome: Addenbrooke’s Cognitive Examination-Revised.
Secondary outcomes: feasibility of recruitment and retention of participants, tolerability and safety of the
interventions, achieving and maintaining the blood pressure and lipid targets, maintaining differences in systolic
blood pressure (> 10 mmHg) and low density lipoprotein-cholesterol (> 1 mmol/l) between the treatment groups,
and performing clinic and telephone follow-up of cognition measures.
Randomisation: using stratification, minimization and simple randomization.
Blinding: participants receive open-label management. Cognition is assessed both unblinded (in clinic) and blinded (by
telephone) to treatment. Adjudication of events (dementia, vascular, serious adverse events) is blinded to management.
Discussion: The PODCAST trial is ongoing with 78 patients recruited to date from 22 sites. Outcomes of cognitive
impairment and dementia are accruing.
Trial registration: ISRCTN85562386
Keywords: Stroke, Post-stroke cognitive impairment, Post-stroke dementia, Blood pressure lowering, Lipid lowering
* Correspondence: philip.bath@nottingham.ac.uk
2Stroke Trials Unit, Division of Clinical Neuroscience, University of
Nottingham, City Hospital campus, Nottingham NG5 1PB, UK
Full list of author information is available at the end of the article
TRIALS
© 2013 Blackburn et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Blackburn et al. Trials 2013, 14:401
http://www.trialsjournal.com/content/14/1/401
Background
Post-stroke cognitive impairment
Post-stroke cognitive impairment is common, ranging
from 17 to 92%, [1,2] and is associated with increased
mortality and decreased quality of life [3-5]. Nevertheless,
cognitive impairment may improve or deteriorate follow-
ing a stroke [6]. Risk factors for cognitive decline include
executive dysfunction, white matter hyperintensities
(WMH), ApoE e4 status [7] and atrophy of crucial brain
areas [8].
Many potential interventions for preventing cognitive
decline have been proposed, including blood pressure
(BP) and lipid lowering, antiplatelet agents, anti-oxidant
vitamins, and cholinesterase inhibitors. Of these, lowering
BP and blood lipids are priorities for testing.
Blood pressure lowering
Lowering BP post-stroke is highly effective in reducing
recurrent and other vascular events, as shown in individ-
ual trials (such as Post-stroke Antihypertensive Treatment
Study (PATS, n = 5,665) and Perindopril protection against
recurrent stroke study (PROGRESS, n = 6,105) [9,10])
and a meta-analysis of them [11]. However, the effect on
cognitive function of lowering BP is far less clear.
Longitudinal studies have shown that premorbid high
systolic blood pressure (SBP) and diastolic blood pressure
(DBP) are associated with WMH and an increased risk of
Alzheimer’s disease (AD) and vascular dementia [12-14].
Although no trials have been expressly designed to test
the effect of lowering BP on subsequent cognition post-
stroke, several have included cognition as a secondary out-
come measure. Whilst potential benefit was seen in the
PROGRESS study [15], none was found in the Prevention
Regimen for Effectively Avoiding Second Strokes trial
(PRoFESS, n = 20,332) [16]. Similar mixed results have
been seen in trials of BP lowering in non-stroke popula-
tions, for example, the Hypertension in the Very Elderly
Trial (HYVET, n = 3,845) and Systolic Hypertension in
Europe (Syst-Eur, n = 4,695) [17,18]. In a meta-analysis
involving both stroke and non-stroke patients, lowering
BP was associated with less cognitive decline, and a
trend to less dementia [19]; meta-regression suggested
that the degree of reduction in cognition was related to
the magnitude of BP lowering.
The Secondary Prevention of Small Subcortical Strokes
(SPS3, n = 3,020) factorial trial of intensive versus guide-
line BP lowering, and aspirin/clopidogrel versus aspirin
[20], in patients with MRI-proven lacunar stroke will be
presenting the effects of intensive BP lowering on cogni-
tion [21] in 2014. The ongoing PRESsure in established
cERebral small VEssel disease (PRESERVE, n = 422) trial
is also investigating the effect of lowering BP in patients
with established cerebral small vessel disease (http://www.
controlled-trials.com/ISRCTN37694103, downloaded 20
June 2013).
Lipid lowering
The majority of information on lipid lowering and cog-
nition relates to statins rather than older interventions
such as fibrates, nicotinic acid derivatives or resins. Statins
have pleiotropic effects that include lowering cholesterol
(specifically low density lipoprotein-cholesterol (LDL-c))
and reducing platelet activity, inflammation and the re-
lease of cytokines and acute phase reactants [22,23].
These effects might limit the progression of Alzheimer’s
pathology from an asymptomatic state to symptomatic,
or deterioration after stroke [24]. Although statins are
one of the most widely prescribed drugs with clear
health benefits in reducing vascular events, including
stroke [25-27], and death, there is little direct evidence
that lipid lowering prevents cognitive decline in either
people with normal cognition or patients with cognitive
impairment.
The Heart Protection Study (HPS, n = 20,536) found sig-
nificant reductions in coronary artery and cerebrovascular
events with simvastatin [28] but there was no difference in
cognition on treatment (baseline measures were not taken
so change could not be assessed), assessed using the Tele-
phone Interview for Cognitive Status (TICS), even when
sub-groups of older patients, and those with prior stroke,
were analysed. Similarly, the Pravastatin in elderly individ-
uals at risk of vascular disease (PROSPER, n = 5,804) trial
in people aged 70 to 82 with vascular risk factors reported
no effect on cognition (measured using Mini Mental State
Examination (MMSE), Stroop and a series of psychometric
tests) [29]. A meta-analysis of three trials found a non-
significant trend to higher MMSE scores in patients with
AD who were randomised to statin treatment (atorva-
statin, simvastatin) [19].
Thus, there is no clear evidence that statins reduce the
risk of cognitive decline or dementia but this has not been
formally examined in a high-risk population. In contrast,
there has been some concern that statins are associated
with reversible cognitive impairment [30], either due to an
idiosyncratic response to statins or an underlying
mitochondrial dysfunction.
Methods/design
Purpose
To develop interventions to prevent cognitive decline
and dementia after stroke.
Primary objectives
Start-up phase
To determine the feasibility of recruiting and retaining
patients, and identify any barriers to achieving BP and
lipid targets.
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Main phase
To determine if ‘intensive’ blood pressure lowering
therapy, and/or ‘intensive’ lipid lowering therapy, after
stroke reduces cognitive decline and dementia.
Secondary objectives
Start-up phase
To determine the feasibility of recruiting and retaining
sites, reaching and maintaining target BP and lipid
levels, performing cognitive assessment in clinic and by
telephone, and the tolerability and safety of the manage-
ment strategies.
Main phase
To determine if ‘intensive’ blood pressure lowering
therapy, and/or ‘intensive’ lipid lowering therapy, after
stroke reduces poor quality of life, poor function, de-
pression, stroke recurrence, vascular events, and death.
Aims
Start-up phase
This is assessing the:
 Ability to deliver the protocol
 Ability to recruit 30 recruiting sites
 Ability to recruit and retain 600 participants
 Ability to achieve and maintain differences in systolic
BP ≥ 10 mmHg and LDL-c ≥ 1 mmol/l between the
‘intensive’ and ‘guideline’ treatment groups
 Ability to perform clinic and telephone follow-up of
outcome measures
 Sensitivity of the Addenbrooke’s Cognitive
Examination-R (ACE-R) and other cognitive
measures to change over time
 Tolerability and safety of the intervention
Main phase
A main phase was planned to assess the safety and efficacy
of intensive versus guideline BP and lipid management in
preventing cognitive decline. A total of 3,400 patients
(start-up 600, main 2,800) post-stroke were planned. How-
ever, the main phase was cancelled 24 months into the
pilot phase because of a failure to achieve a sufficiently
high recruitment rate.
Design
PODCAST is a multi-centre prospective randomised
open-label blinded-endpoint controlled partial-factorial
phase IV trial. The study is conducted according to the
principles of the Declaration of Helsinki and ‘International
Conference on Harmonisation of Good Clinical Practice’.
Study approval by national (UK, approval 09/H0403/71,
date 12 November 2009) and local research ethics com-
mittees (all centres) has been obtained. As a management
trial, the study does not fall under the remit of the UK
Medicines and Healthcare Products Regulatory Authority
(as confirmed by them). The management of personal
data adheres to the UK Data Protection Act 1998. The
UK National Institutes Health Research Stroke Research
Network supports the trial through screening and re-
cruitment of patients (23 September 2009).
Patient population
Participants are recruited from hospital-based stroke
services, and are consented for a face-to face assessment
of cognition (telephone-Mini Mental Status Examin-
ation, t-MMSE) and function (modified Rankin Scale,
mRS) at 8 to 26 weeks after the stroke. If the participant
is eligible and interested after the initial assessment,
fasting lipids, glucose, urea and electrolytes, and HbA1c
are tested.
Inclusion criteria
1. Age > 70 years and t-MMSE > 16 (maximum score
22); or age > 60 years and t-MMSE 17 to 20
2. Functionally independent (mRS 0 to 2).
3. Ischemic stroke (IS, any Oxfordshire Community
Stroke Project or Trial of Org10172 in Acute Stroke
Treatment type [31,32]) or spontaneous
intracerebral haemorrhage.
4. Three to seven months post-event (to allow cognitive,
neurological, BP and lipid stabilisation [33], but avoid
attrition).
5. Systolic BP 125 to 170 mmHg.
6. Total cholesterol (TC) 3 to 8 mmol/l.
7. Presence of an informant (ideally two): partner,
sibling, child, friend (for Informant Questionnaire on
Cognitive Decline in the Elderly, IQCODE [34]).
8. Capacity and willingness to give consent.
Exclusion criteria
1. Participants not meeting inclusion criteria.
2. Subarachnoid haemorrhage.
3. Secondary intracranial haemorrhage (trauma,
arterio-venous malformation, cavernoma).
4. No CT/MR brain scan within ten days of index
stroke.
5. Inability to give consent or do study measures, for
example, severe dysphasia, weakness of dominant
arm.
6. Profound deafness.
7. Severe hypertension (systolic BP > 170 mmHg).
8. Definite need for ‘intensive’ BP control.
9. Severe hypercholesterolemia (TC > 8 mmol/l).
10. Definite need for, or demonstrated intolerance of,
‘high intensity’ statin.
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11. Definite need for a cholinesterase inhibitor for
dementia.
12. Familial stroke associated with dementia, for
example, CADASIL.
13. Chronic renal failure: eGFR < 45 (or eGFR < 37 in
people of African/Afro-Caribbean origin).
14. Liver disease, ALT > three times upper limit of
normal, using local laboratories ranges.
15. Ongoing participation in trials involving drug and/
or devices. Participants already in another trial may
be recruited to PODCAST, provided that
participation in the other trial is complete prior to
PODCAST randomisation.
16. Any serious medical co-morbidity (for example,
active malignancy) such that the life expectancy
is < 24 months.
17. Clinically unstable at the time of enrollment.
18. Dementia.
Informed consent
All participants must have capacity, and be willing and
able to provide written informed consent. Participants
are screened for potential recruitment during their initial
presentation to the hospital stroke services, and are
given an information sheet explaining the study.
Screening consent
Informed consent for formal screening is taken in hospital
for conducting the following assessments, 8 to 26 weeks
after their stroke:
 Assessment of cognition - t-MMSE
 Assessment of function - mRS
 Blood test - fasting lipids, glucose, urea and
electrolytes, HbA1c
The availability of an informant (partner, sibling, child
or friend), ideally with a backup, is key. Informants pro-
vide information on the participant’s prior cognitive
state and decline (via the IQCODE).
Both the patient and informant are then given informa-
tion sheets to take away and review.
Full consent
Providing the patient fulfils the inclusion–exclusion cri-
teria at the screening visit, full consent is taken at the
baseline visit. This includes an assessment of capacity
by telling the patient about the trial and then asking
them to answer questions based on this information:
 What condition? Stroke
 What is the trial trying to prevent? Dementia
 What are the interventions? Intensive BP and/or
lipid lowering
Following any questions about the trial, written in-
formed consent of both the patient and informant is
then performed. Patients may also give consent for two
sub-studies:
 Ambulatory BP monitoring
 On-treatment CT scan
Part of the consent process involves both the patient
and informant agreeing to the latter assuming the right
of proxy consent if the patient loses capacity during the
trial.
Randomisation
Eligible and consenting participants are randomised
centrally using a secure internet site in real-time: https://
www.nottingham.ac.uk/~nszwww/podcast/podcasttrialdb/
podcast_login.php.
The process of randomisation includes stratification,
minimisation and simple randomisation, based on in-
formation gathered by the local recruiting investiga-
tors. Stratification and minimisation allow for improved
matching at baseline: stratification allows variable cat-
egories to be treated as nested trials in their own right;
minimisation increases statistical power [35]. Simple
randomisations reduce predictability. The minimisation
variables will be used for adjustment of the primary and
secondary analyses.
Stratification
 Stroke type (IS, spontaneous ICH)
Patients with IS are randomised to both BP lowering
(intensive versus guideline) and lipid lowering (intensive
versus guideline) strategies.
Patients with ICH are randomised to BP lowering
(intensive versus guideline) strategy only.
Minimisation (on key prognostic/logistical variables)
 Age (< 70/> 70 years)
 Sex (female, male)
 Dysphasia (no, yes)
 Cognition, ACE-R (≥ 85/< 85)
 Systolic BP (< 150 / > 150 mmHg)
 Total cholesterol (< 4.0/≥ 4.0 mmol/L)
 Function/dependency, mRS (0/≥ 1)
 Brain region (subcortex/cortex)
 Evidence of periventricular white matter lucency
(no, yes)
 Time since index stroke (< 140/> 140 days)
 Number of antihypertensive drugs (< 2/≥ 2)
 Already on a statin (yes, no)
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Simple randomisation
On 5% of patients at time of minimisation.
Randomisation groups
Study participants are randomized to:
 Intensive versus guideline BP lowering - all
participants
 Intensive versus guideline lipid lowering - ischaemic
stroke only
As a result, patients can be randomised to one of six
groups:
1. Intensive BP lowering and intensive lipid lowering
(ischaemic stroke only)
2. Intensive BP lowering and guideline lipid lowering
(ischaemic stroke only)
3. Intensive BP lowering only (ICH only)
4. Guideline BP lowering and intensive lipid lowering
(ischaemic stroke only)
5. Guideline BP lowering and guideline lipid lowering
(ischaemic stroke only)
6. Guideline BP lowering only (ICH only)
Assuming that approximately 10% of patients will be
enrolled with ICH, the distribution of patients between
the six treatment groups will, for every 100 patients,
approximate to 22.5% in each of the four groups of is-
chaemic stroke patients (intensive versus guideline BP;
intensive versus guideline lipid) and 5% in each group
of patients with ICH (intensive versus guideline BP).
Interventions
The trial is assessing management strategies (‘intensive’
versus ‘guideline’) rather than particular drugs. All partici-
pants receive standard lifestyle advice and rehabilitation
(as per NICECG 68, 2008 [36]) including: diet, exercise,
smoking advice, rehabilitation, psychological assessment
and therapy, modification of all risk factors and other
relevant interventions.
Guideline management
Participants randomised to the guideline groups are
managed by their general practitioner (GP) who follows
national/international guidelines and local practice.
Guideline BP lowering
It is expected that GPs will aim for a systolic BP <
140 mmHg.
Guideline lipid lowering
It is expected that GPs will aim for a LDL-c < 3 mmol/l
(or TC < 5 mmol/l).
Intensive management
Participants in the intensive group are managed by the
local hospital stroke research team and medications
initiated by the local investigator and continued by the
GP. The trial does not stipulate specific drugs but gives
examples of drugs (and relevant doses) to use from the
different drug classes. Guidance on which drugs to start
and add, how to titrate, and how to manage participants
with various contra-indications to medications, are in-
cluded in algorithms; these are updated to include new
information as relevant.
Intensive BP and lipid management strategies may be
attenuated or stopped if the patient or their informant
withdraws consent, for safety, or if unacceptable adverse
events develop. If the participant wishes to withdraw
from treatment, they are requested to permit primary
outcome data to be collected, ideally at the end of the
follow-up period.
Intensive BP lowering
Two targets are required for intensive BP lowering:
 Systolic BP < 125 mmHg
 Difference in systolic BP between intensive and
guideline groups > 10 mmHg
Additional guidance on salt and alcohol restriction,
and weight reduction is given. The intensive BP treat-
ment algorithm is based on NICE guidelines relating to
stroke (CG68 2008 [36]), hypertension (CG127 2011)
and type 2 diabetes (CG66 2006, partially updated by
CG87 [37]). The algorithm is only a guide and investi-
gators may choose other medications depending on
local policy and practice as long as they fit with the
overall design of the trial, that is, to achieve intensive
BP lowering.
Suitable drug classes and example drugs are:
 ‘A’ = angiotensin converting enzyme inhibitor
(ACE-I, for example, perindopril 2 to 8 mg daily
(od), ramipril 1.25 to 5 mg twice daily (bd)) or
angiotensin receptor antagonist (ARA, for
example, losartan 25 to 100 mg od, candesartan 8
to 32 mg od)
 ‘B’ = beta (β)-receptor antagonist (for example,
atenolol 25 to 100 mg od, bisoprolol 5 to
20 mg od)
 ‘C’ = calcium channel blocker (for example,
amlodipine 5 to 10 mg od, nifedipine LA 30–60 mg
od, verapamil SR 120 to 240 mg od)
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 ‘D’ = diuretic (for example, bendroflumethiazide
2.5 mg od, hydrochlorothiazide 12.5 mg od,
indapamide 2.5 mg od)
 ‘K’ = potassium-sparing diuretics (for example,
spironolactone 12.5 to 100 mg od, amiloride 5 to
20 mg od)
 ‘Z’ = alpha (α)-receptor antagonists (for example,
doxazosin 4 to 16 mg od)
 ‘M’ = centrally acting drugs (for example,
moxonidine 200 to 600 μg daily in divided doses)
In the absence of contraindications, participants should
be started on either:
 An ‘A’ drug, with subsequent addition of a ‘C’ then
‘D’ drug (as required)
 A ‘C’ drug, with subsequent addition of an ‘A’ then
‘D’ drug (as required)
If additional treatment is needed to reach target, fourth-
line and additional options include:
 Add a K or Z drug, then the other
 Add an ‘M’ drug
Intensive lipid lowering
Two targets are required for intensive lipid lowering:
 Calculated LDL-c < 1.4 mmol/l
 Difference in LDL-c between intensive and guideline
groups > 1.0 mmol/l
If LDL-c cannot be calculated (for example, due to
an elevated triglyceride level), targets for TC are used
instead:
 TC < 3.1 mmol/l
 Difference in TC between intensive and guideline
groups > 1.0 mmol/l
Drug therapy for the intensive lipid arm will typically
comprise:
 A third-generation statin (for example, atorvastatin
80 mg od) [38]
 Then add ezetimibe (10 mg od)
 Then add a resin
Additional guidance on the use of plant stanols/sterols
as part of meals, and weight reduction is given. The al-
gorithm for intensive lipid reduction builds on NICE
guidelines (CG67, 2008 [39], ezetimibe [40]). Again, the
algorithm is only a guide and investigators may choose
other treatment strategies depending on local policy
and practice as long as they fit with the overall design of
the trial, that is, to achieve intensive lipid lowering.
Standard care
Participants receive standard evidence-based care on top
of the interventions, including (as appropriate):
 IS: anticoagulation (cardioembolic stroke),
antiplatelets (other IS), carotid endarterectomy
Blood pressure and lipid measurements
Blood pressure (BP)
BP measurements are performed using a validated auto-
mated BP monitor, for example, Omron 705CP or 705CP
II. These devices have been validated by the British Hyper-
tension Society [41], and were used in the positive ASCOT
hypertension mega-trial involving 20,000 patients [42].
Baseline and follow-up systolic and diastolic BP and heart
rate (HR) readings are taken by trained staff in the non-
paretic arm with the participant sitting (three readings)
and then standing (one reading).
Ambulatory BP monitoring (ABPM)
In centers with ABPM equipment (for example, SpaceLabs
90207), participants have 24 hour ABPM performed at
baseline and than on treatment every six months. Twenty-
four hour, day-time (07.00 to 23.00 thrice hourly) and
night-time (23.00 to 07.00 hourly) ABPM data are re-
corded. From these, a number of measures are calculated:
 Mean SBP, DBP and HR for each time interval
 Peak SBP and HR profile over 24 hours
 BP and HR variation as standard deviation and
coefficient of variation (= SD/Mean)
Lipid measurement
Fasting lipids are measured at an accredited clinical bio-
chemistry laboratory. Fasting should be performed over-
night and measurements made at least one month after
the last change in lipid lowering therapy. Lipid measure-
ments utilize standard techniques and comprise:
 TC
 Triglyceride (TG)
 HDL cholesterol (HDL-c)
 LDL-c (calculated)
Outcome measure
Screening
An abbreviated form of the t-MMSE is used to screen
patients so that those with dementia are excluded.
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Primary outcome
The primary outcome is the Addenbrooke’s Cognitive
Examination-Revised (ACE-R), which includes the MMSE.
The ACE-R is measured at baseline and at each six-month
research clinic visit.
Secondary outcomes
These are assessed at baseline and at each six-month
research clinic visit.
 Cognitive outcomes, participant: MoCA, TICS,
Stroop and trail-making A and B
 Cognitive assessment, informant: IQCODE
 Cognitive impairment (ACE-R < 89)
 Cognitive decline (reduction in ACE-R by ≥ 10, or
ACE-R < 89)
 Dementia (DSM IV)
 Quality of life: Euro-Qol (EQ-5D and EQ-VAS). A
health utility status will be calculated from the
EQ-5D using the UK version of the time trade-off
algorithm
 Mood: Zung Depression rating Scale (ZDS, short
form)
 Function: modified Rankin Scale (mRS), Barthel
Index (BI)
 Health resource utilisation: face-to-face survey with
participant and carer
 Vascular event: stroke recurrence (by type),
myocardial infarction (MI), peripheral arterial
disease (PAD)
 Serious adverse events (SAE)
 Disposition: home, home with carer, residential
home, nursing home, hospital, death
 Haemodynamics: blood pressure, heart rate
 Blood: fasting lipids (TC, TG, HDL-c, LDL-c)
 Blood: Urea and electrolytes, glucose, HbA1c
A head CT/MR scan is performed once participants
have been in the trial at least twelve months (six months
minimum). Comparison of this with the index stroke
CT scan will allow changes to be identified: new stroke
lesions, white matter disease, atrophy.
Dementia, vascular events, and brains scans are adju-
dicated by experts blinded to treatment assignment.
All patients are registered with the Office for National
Statistics to identify death and its certified cause.
Sample size calculation
Start-up phase
Recruitment of 600 participants (300 per BP group, ap-
proximately, 270 per statin group) will be sufficient to
demonstrate adequacy in recruitment of sites and par-
ticipants, whether sufficient on-treatment differences
in BP and lipids can be obtained and maintained, and
whether cognition can be assessed satisfactorily. No
formal sample size calculation is relevant to this part
of the trial.
Main phase
Using the ACE-R, expanded to include death, as the pri-
mary outcome, the whole trial (start-up plus main phases)
will need a sample size of 3,400 (1,700 per BP group) post-
stroke participants, assuming:
 Significance, α = 5%
 Power (1-β) = 90%
 Rate of cognitive impairment or death in guideline
BP group = 25% at five years (main trial, average
length of follow-up four years) [34]
 Rate of cognitive impairment or death in ‘intensive’
BP group = 20%, that is, absolute risk reduction
(ARR) = 5% (number-needed-to-treat = 20), relative
risk reduction (RRR) = 20%
 Losses to follow-up = 3%
Hence, 765 participants (0.225 × 3,400) are anticipated
to develop cognitive impairment or die. The sample size
allows a smaller but clinically worthwhile decline in
cognitive decline to be identified with 80% power, that
is, ARR = 4.5% (RRR 18%). Since there are less existing
data on the effect of cholesterol lowering on cognition, the
statin factor will assume the same RRR (20%) but have less
power (approximately 86%) since it will only involve
participants with ischemic stroke (approximately 3,060).
Changing from a binary to ordinal analysis of cognitive
outcomes may allow for a reduction in sample size of up
to 30%, as seen in the ‘Optimizing Analysis of Stroke
Trials’ (OAST) collaboration for functional outcome
after stroke [43]. Providing ordinal analysis appears to be
more efficient than binary analysis for cognition data,
the trial will be re-sized according to the method of
Whitehead [44]. Analyses will be adjusted for the covari-
ates since this approach increases statistical power [45]
and is recommended by the European Agency for the
Evaluation of Medicinal Products (EMEA) Ref CPMP/
EWP/560/98). Any such decision to change will be per-
formed prior to database lock, blinded to treatment, and
defined explicitly in the Statistical Analysis Plan.
Statistical analysis
Feasibility of start-up phase
The feasibility criteria listed in section 2.4.1 are reviewed
during the trial. A review at 24 months found that there
was no chance of recruiting 600 patients during the in-
ternal pilot and that, therefore, the planned main phase
should be cancelled (see section 4).
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Comparisons between treatment groups
Outcomes will be compared between the treatment
groups by intention-to-treat (ITT):
 Intensive versus guideline BP lowering
 Intensive versus guideline lipid lowering
Analyses will be adjusted for baseline values and
stroke type, age, sex, SBP, TC, and time from stroke to
randomization. Continuous covariates (age, SBP, TC, time)
will be used with their raw data, that is, not dichotomized.
(The full set of stratification and minimization variables
listed in section Randomisation will not be used for adjust-
ment because of the limited anticipated sample size of ap-
proximately 100).
Missing data, and death
Missing data will not be imputed. Participants who die will
be assigned discrete values for outcome measures with a
value worse than any living value (as is standard for mRS,
BI). This avoids giving death the same value as the worst
possible outcome when alive (best to worst) or, worse, ex-
cluding patients who die (since many dementia trials have
been confounded by losses to death). Hence, patients who
die will be included in all analyses. The EQ-5D Health
Utility State (HUS) gives death a score of 0.
 Addenbrooke’s Cognitive Examination-Revised
(ACE-R), 100 to 0 with death = −1
 Mini-Mental State Examination (MMSE), 30 to 0
with death = −1
 Telephone-Mini Mental Status Examination
(t-MMSE), 18 to 0 with death = −1
 Telephone Interview for Cognitive Status (TICS), 37
to 0 with death = −1
 Stroop (accuracy), 24 to 0 with death = −1
 Trail-making (accuracy) [46], 25 to 0 with death = −1
 Modified Rankin Scale (mRS), 0 to 5 with death = 6
 Barthel Index (BI), 100 to 0 with death = −5
 EuroQol EQ-5D Health Utility State (HUS), 1
to −0.594 with death = 0
 EuroQol Visual Analog Scale (EQ-VAS), 100 to 0
with death = −1.
 Zung Depression Scale (ZDS), 25 to 100 with
death = 102.5
 Verbal fluency (animal naming), x to 0, with
death = −1
Primary outcome
Comparison of ACE-R (extended to include death - sec-
tion Missing data, and death) between ‘intensive’ and
‘guideline’ BP/lipid lowering groups using multiple linear
regression and with adjustment (section Comparisons
between treatment groups).
Secondary analyses
Dichotomous, ordered categorical, continuous and time to
event data will be analysed using binary logistic regression
(BLR), ordinal logistic regression (OLR), multiple linear
regression (MLR) or Cox regression (CR) respectively, and
with adjustment (section Comparisons between treatment
groups). 95% confidence intervals will be given and
P < 0.05 will be considered statistically significant.
The proportion of participants with cognitive impair-
ment or who have died, and cognitive decline or died, will
be compared between the treatment groups, as done pre-
viously for MMSE (a subset of ACE-R) [15,28]. Neverthe-
less, where possible, continuous or ordinal outcomes will
be used in preference to dichotomous outcomes.
Governance and funding
Trial Steering Committee (TSC)
The TSC provides leadership for the trial and determines
and monitors the overall strategy. It meets annually, and
has teleconference or Email discussions as needed.
Data Monitoring Committee (DMC)
The DMC reviews unblinded data annually in respect of
safety and efficacy, and considers the study in the context
of other trials of dementia prevention post-stroke. It meets
at least annually.
Trial Management Committee (TMC)
The Trial Management Committee (TMC) runs the trial,
with meetings every three weeks. It is unblinded to BP
and lipid levels, and communicates with the Trial Steering
Committee (TSC) and investigators as to whether targets
are being met.
Adjudication committees
All adjudication is performed blinded to treatment
assignment:
 Dementia is adjudicated by a group of three
individuals (AB, CB, GF); each adjudicator sees each
event
 Vascular events are adjudicated by a group of three
individuals (PP, AM, RH); each adjudicator sees each
event
 Serious adverse events are adjudicated by one of two
adjudicators (NS, TE)
Sponsor
The University of Nottingham is the trial’s sponsor.
Funding
The start-up phase of PODCAST is funded jointly and
equally by the UK Alzheimer’s Society and UK Stroke
Association.
Blackburn et al. Trials 2013, 14:401 Page 8 of 11
http://www.trialsjournal.com/content/14/1/401
Trial Status
A lower than planned recruitment of sites and patients
has meant that the aspiration to recruit 600 patients
over two years has not been realized. A number of
reasons explain the poor recruitment:
 Research governance issues. The trial requires both
acute hospital trusts (who identify patients, manage
intensive BP and/or lipid lowering, and perform
clinic follow-ups) and general practices, through
Primary Care Trusts (PCTs, who manage guideline
BP and/or lipid management), to sign-up. In general,
each acute trust is associated with between one and
three PCTs so that approval for each recruiting site
requires between two and four agreements and
contracts. It has proved difficult to coordinate the
agreement to deliver the study in a locality between
these acute and community trusts.
 NHS Excess Treatment Costs. PCTs were often
unwilling to approve payment of treatment costs,
often citing the cost of atorvastatin (which is now
generic but was not so at the start of the trial).
 Long-term follow-up. Once a cohort of patients is
recruited, each patient needs follow-up (which
Table 1 Protocol amendments and other changes to trial practice
Criterion Previous versions Current version/status Reason
Protocol changes
Posterior circulation
stroke (POCS)
Excluded Included To expand the inclusion criteria; posterior
circulation stroke can lead to cognitive decline
Exclusion of NYHA 3 or 4 Exclusion criterion Removed To simplify protocol
LDL-c target < 2.0 mmol/l < 1.4 mmol/l Half of patients already at LDL-c < 2 at
baseline
Total cholesterol < 4.0 mmol < 3.1 mmol/l Ditto
Glucose monitoring Glucose, HbA1C Some BP and lipid drugs may reduce, or
cause, diabetes mellitus
Quality of life DEMQOL Removed To simplify protocol
Screening As telephone call As research clinic visit To reduce recruitment of ineligible patients
Time from screening
to randomisation
2 weeks 1 week To accelerate recruitment
Guideline statin dosage Simvastatin 40 mg, pravastatin
40 mg, fluvastatin 40 mg
Simvastatin 10 to 40 mg, pravastatin
10 to 40 mg, fluvastatin 10 to 80 mg
To reflect NICE guidelines on lipid
management (CG 67, 2008)
Statin classification Guideline statin: Guideline statin: To clarify intensive versus guideline lipid
lowering management
simvastatin < 40 mg, pravastatin
any dose, fluvastatin any dose,
atorvastatin 10 mg.
simvastatin ≤ 40 mg, pravastatin any
dose, fluvastatin any dose,
atorvastatin≤ 20 mg.
Intensive statin:
atorvastatin≤ 40 mg
Intensive statin: atorvastatin > 20 mg,
rosuvastatin any dose
Trial duration and
participant involvement
8 years 4 years To shorten trial since the main phase is no
longer justified
BP and lipid management
in follow-up visits
‘Floating’ visit at any time outside the
planned visits at 3, 6, 12, 18, 24, 30,
36 and 42 months
To allow enhanced escalation of treatment, as
appropriate
Baseline and follow-up BP
and HR monitoring
Three measurements in rapid
succession
Four measurements in rapid
succession including one standing
To detect postural hypotension
Neuroimaging sub-study
scan
CT scan on treatment (plus collection
of any clinical scans during treatment)
To detect potential affects on atrophy, white
matter changes
Follow-up visits Seen in clinic once a year with
interval blinded telephone
follow-up.
Seen in clinic once every 6 months To assess latest BP and/or lipid levels and
escalate treatment as appropriate
Other changes
Minimisation variables As in section Minimisation (on
key prognostic/logistical
variables) above
Age, systolic BP, LDL-c Small trial size precluded numerous
minimisation variables
Email reminders Twice yearly to investigators. To highlight the need to achieve targets in BP
and lipid lowering in patients randomised to
intensive management
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typically last two and a half hours) every six months,
thereby placing a considerable work load on
research staff at acute sites.
 Changes to the original protocol are summarised in
Table 1
Abbrevations
PODCAST: Prevention of Decline in Cognition after Stroke Trial;
TICS: Telephone Interview for Cognitive Status; MOCA: Montreal Cognitive
Assessment; ACE-R: Addenbrooke’s Cognitive Examintaion-revised;
MMSE: Mini-Mental State Examination; od: once daily; bd: Twice daily;
PCT: Primary Care Trust; IQCODE: Informant Questionnaire on Cognitive
Decline in the Elderly; DSM IV: Diagnostic and Statistical Manual of Mental
Disorders edition IV; BP: Blood pressure; SBP: Systolic Blood Pressure;
DBP: Diastolic Blood Pressure; ABPM: Ambulatory Blood Pressure Monitoring;
HR: Heart rate; MI: Myocardial infarction; PAD: Peripheral arterial disease;
eGFR: estimated Glomerular Filtration Rate; ALT: ALanine Transaminase;
IS: Ischaemic stroke; ICH: Intracerebral haemorrhage; SAE: Serious adverse
events; GP: General practitioner; WMH: White matter hyperintensities;
POCS: Posterior Circulation Stroke; ARR: Absolute risk reduction;
NNT: Number-needed-to-treat; RRR: Relative risk reduction; ITT: Intention-to-
treat; CT: Computed Tomography; MR: Magnetic Resonance imaging;
TC: Total cholesterol; TG: Triglycerides; HDL-c: High Density Lipoprotein
cholesterol; LDL-c: Low Density Lipoprotein cholesterol; OAST: Optimizing
Analysis of Stroke Trials’; EMEA: European Agency for the Evaluation of
Medicinal Products; BLR: Binary logistic regression; OLR: Ordinal logistic
regression; MLR: Multiple linear regression; CR: Cox regression; mRS: Modified
Rankin Scale; BI: Barthel Index; HUS: EuroQol EQ-5D Health Utility State;
ZDS: Zung Depression Scale; TMC: Trial Management Committee; TSC: Trial
Steering Committee; DMC: Data Monitoring Committee.
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